AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 261 min read$UTHR

United Therapeutics Insider Sold Shares Worth $5,536,235, According to a Recent SEC Filing

An insider of United Therapeutics sold shares worth $5,536,235, as disclosed in a recent SEC filing. The company's stock is currently trading at $592.84, with a 5-day change of +0.91%, a 1st Jan change of +9.15%, and a year-to-date change of +21.67%.

Original reporting
marketscreener.com
Published Oct 26, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
4/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed insider sale adds a modest bearish signal but is unlikely to move the stock significantly.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: after market close

Background

United Therapeutics (UTHR) is a biotech firm focused on pulmonary and rare disease therapies.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

SEC Form 4 shows United Therapeutics insider sold shares worth $5,536,235.

Expected impact

likely modest pressure as investors price in the insider sell.

Evidence & confidence

The sale size is moderate ($5.5M) and typical insider sales can cause short-term downside.

Market effects

Sector

Minimal impact on biotech/healthcare sector.

Regional

No regional effect beyond United Therapeutics.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The insider may be diversifying, not a lack of confidence; price could hold.

Key entities

  • company
    United Therapeutics

    Issuer of the insider sale.

Read at source← All news

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min